Cat’s Whiskers Safety: Kidney Cautions and Interactions

Cat’s whiskers has a good safety record. That should be said first and without qualification: Orthosiphon aristatus leaf has been drunk daily across Indonesia, Malaysia, Vietnam and Thailand for as long as anyone has recorded it, and sold as a licensed pharmacy product in several European countries for decades. The European monograph lists undesirable effects as none known and records no overdose cases. This is not a herb with a body count, and a page that implied otherwise would be inventing a hazard.

What it does have is a targeting problem, and it is the reason this page exists. A herb marketed for the kidneys is bought disproportionately by people who are worried about their kidneys — which means the population most likely to drink it is the population in whom a diuretic and an extra potassium load are least safe. The risk is not in the plant. It is in the overlap between who it is sold to and what it does. Everything below follows from that single observation.

The Paradox at the Centre of This Herb
What the Safety Record Actually Says
The Potassium Arithmetic, Done Honestly
Why a Small Number Still Matters
When the Mechanism and the Hazard Are One Property
Tea or Capsule: Which Carries the Potassium?
Chronic Kidney Disease
Heart Failure and Fluid Restriction
Drug Interactions
What Has Never Been Tested
Hazards Cat’s Whiskers Does Not Have
Identity: Why a Certificate Does Not Settle It
“Supports Kidney Function” Is Not a Measurable Claim
Practical Rules
Key Research and Reference Sources
Connections

The Paradox at the Centre of This Herb

Read the European monograph’s contraindication and then read a supplement listing for the same plant, side by side.

The monograph contraindicates it in “conditions where a reduced fluid intake is recommended, e.g. severe cardiac or renal disease.”

The shelf sells it as kidney support, kidney cleansing, and a herb for people whose kidneys are struggling.

Those two statements are aimed at the same person. That is not a subtlety; it is a direct contradiction between the regulatory file and the marketing, and it is the single most useful thing to notice about this plant. A reader with early kidney disease who searches for a kidney herb will find cat’s whiskers near the top of the results, and will find the contraindication that names their condition only if they go looking for the monograph.

Two claims on the same shelf cancelling each other is a pattern worth checking on any herb. Here it takes an unusually clean form: the herb’s selling point and its formal contraindication describe the same group of people.

It is worth being clear about who is not affected. Somebody with normal kidneys, no heart failure, no relevant prescriptions and a normal diet, drinking a couple of cups a day for a fortnight, is in the population this herb has been used safely by for centuries. Most of this page does not apply to them.

What the Safety Record Actually Says

Refusing to manufacture hazards is as much a part of accuracy as naming real ones, so here is the exculpatory side, stated properly.

Long, high-volume, everyday use. This is not an obscure herb rediscovered from a manuscript. It is one of the most-consumed medicinal teas in Southeast Asia, drunk casually and daily by a very large number of people over a very long period. A serious acute toxicity would have surfaced.
Decades of licensed European sale as a pharmacy product with a package leaflet, in Germany, France, Poland and elsewhere, under pharmacovigilance.
The monograph lists undesirable effects as “none known” and records no cases of overdose.
No hepatotoxicity signal. Unlike several herbs in the wider supplement market, this one does not carry a cluster of liver-injury case reports.

Two translations are required before that list is read as reassurance, and they cut in a specific direction rather than a general one.

“None known” describes surveillance, not biology. Undesirable effects are “none known” partly because nobody has run a study designed to find them. Long traditional use is genuinely good evidence against common, acute, obvious harm — that is exactly what it is good at detecting. It is weak evidence about slow harms, about rare harms, and about harms in medicated populations that did not exist when the tradition formed.

The tradition formed before ACE inhibitors. Centuries of safe use in Java tell you nothing about the safety of the same tea in someone taking ramipril and spironolactone with an eGFR of 28. That combination is forty years old, not four hundred. The gap between the evidence base and the modern user is the whole problem.

The Potassium Arithmetic, Done Honestly

Cat’s whiskers leaf is, chemically, a potassium-rich plant — potassium is its single most abundant characteristic constituent, at roughly 3% of the dried leaf per the European assessment report. Herbal safety writing tends to leave that figure unconverted, which lets it sound alarming. Convert it.

Assumptions, printed so you can check them: 3% potassium by dry weight; the top of the European daily range, 12 g of dried herb; and, for the moment, complete transfer of that potassium into the cup.

12 g × 3% = about 360 mg of potassium per day, at the maximum dose, assuming everything extracts.

For orientation: a medium banana carries roughly 400 mg, a medium baked potato considerably more, and an adult reference intake is in the region of 3,500 mg a day. So the full licensed daily dose of this herb delivers less potassium than one banana, and only a fraction of it actually leaves the leaf in a domestic infusion.

That is the honest number, and it deflates the scariest version of the warning. For anyone with normal kidney function, the potassium in cat’s whiskers is nutritionally trivial and, if anything, mildly favourable — most people eat too little potassium, not too much. See Potassium.

We will not go further and state how much potassium a given cup contains. Transfer efficiency depends on leaf particle size, water volume, temperature and steeping time, and we know of no published assay measuring it for this herb. A confident milligrams-per-cup figure would be a guess.

Why a Small Number Still Matters

Having deflated the number, here is why it is not zero-risk, stated precisely rather than dramatically. The hazard is not the size of the potassium load. It is that it is an uncounted load in people who are counting.

Someone with advanced chronic kidney disease is frequently given a potassium target and a list of foods to restrict — bananas, potatoes, tomatoes, oranges, dried fruit. Those lists are followed with real effort. Nobody puts herbal tea on them, because tea does not read as food. So 360 mg a day arrives outside the accounting, in a person whose whole dietary strategy depends on the accounting being roughly right. Against a restricted budget, that is a meaningful percentage from a source the patient believes is helping their kidneys.

Three further factors turn a small load into a real one:

Stacking. The relevant question is never the herb alone. It is the herb plus an ACE inhibitor plus a potassium-sparing diuretic plus a salt substitute (most of which are potassium chloride) plus reduced excretion. Each contribution is modest; hyperkalaemia arrives from the sum.
Chronic use. The licence says two weeks. A daily beverage habit runs for years. Every serious version of this risk involves someone drinking it indefinitely, not for a fortnight.
Hyperkalaemia is silent. It typically produces no symptoms until it is severe, and its first manifestation can be a cardiac arrhythmia. There is no warning sensation to stop on. See Potassium Toxicity.

That is the accurate shape of the concern: not a poisonous plant, but an unlabelled contribution to a balance that some readers are actively trying to manage, and cannot feel going wrong.

When the Mechanism and the Hazard Are One Property

There is a neat and uncomfortable symmetry here, and it deserves to be stated on its own.

The proposed explanations for the herb’s diuretic effect include its potassium load; potassium salts of organic acids promote a mild natriuresis and alkalinise urine. If that is the mechanism — and it is one of the more plausible candidates, given how poorly the marker flavones dissolve in water — then the constituent responsible for the benefit is the same constituent responsible for the risk. The potassium is why it might work and why it must not be drunk freely in kidney failure. One property, described twice, once on the front of the packet and once in the contraindications.

The same logic applies to the diuresis itself. An agent that increases urine output is useful for flushing and dangerous for someone on a fluid restriction. There is no version of this herb that keeps the licensed effect and drops the contraindication, because they are the same effect seen from two different clinical situations.

This is a general principle worth carrying to other herbs. Where a benefit and a caution trace to one mechanism, no formulation or dose adjustment separates them — only choosing the right person does.

Tea or Capsule: Which Carries the Potassium?

A practical question follows, and the honest answer is partly reasoned and partly unknown.

Potassium exists in the leaf as soluble mineral salts. Hot water extracts them efficiently — this is why leaching vegetables in water is a standard technique in renal diets. So a hot-water infusion and an aqueous dry extract would be expected to carry the potassium through, while a high-percentage ethanolic extract would be expected to leave most of it behind, since inorganic salts are poorly soluble in concentrated ethanol.

If that expectation holds, it produces a genuinely counter-intuitive conclusion: for a reader who must limit potassium, an ethanolic dry extract may be the safer preparation, and the traditional tea the riskier one. That inverts the usual assumption that the traditional form is the gentle option.

We flag this as chemistry-based expectation, not measurement. No label we are aware of reports potassium content per dose for any Orthosiphon product, and we have found no published assay comparing the mineral content of aqueous and ethanolic extracts of this leaf. That is itself a finding worth stating: a herb whose most abundant characteristic constituent is potassium is sold in multiple preparations, none of which declares how much potassium it delivers. Anyone on a potassium restriction should treat every form as unquantified and ask their renal dietitian rather than rely on this reasoning.

Chronic Kidney Disease

This is the group the whole page is written for. The position is straightforward:

If you have chronic kidney disease of any stage, do not start this herb without agreement from the clinician who manages it. That is not defensive boilerplate; three specific things change with reduced kidney function.

Potassium excretion falls. A failing kidney cannot clear a potassium load the way a healthy one can, so contributions that are irrelevant at eGFR 90 stop being irrelevant. This becomes clinically important in the more advanced stages and is compounded by the drugs commonly prescribed alongside.
Fluid handling changes. Some people with kidney disease are told to drink more; others, particularly with heart failure or advanced disease, are told to drink less. A herb whose entire licensed purpose is to increase urine output while you drink more water is directly opposed to the second instruction.
Everything is being measured. Kidney disease is managed by numbers — eGFR, potassium, bicarbonate, urine albumin. Introducing an unquantified variable into a carefully monitored system makes the numbers harder to interpret, quite apart from any direct effect.

If you take it anyway, the minimum sensible precaution is to tell the clinician and have potassium and kidney function checked a few weeks in, rather than at the next routine appointment. See Kidney Disease, Acute Kidney Injury and Kidney Function Tests.

A separate and easily missed point: people with kidney disease are also, statistically, people with diabetes and high blood pressure. That means they are the readers most exposed to the herb’s unquantified metabolic and blood-pressure claims as well — discussed on the research page. See also Type 2 Diabetes.

Heart Failure and Fluid Restriction

The monograph names severe cardiac disease alongside renal disease, and the reasoning is the same. People with heart failure are frequently on a fluid restriction, a sodium restriction and one or more diuretics, with a target weight they check daily. Adding an unmeasured aquaretic to that is adding noise to a system that is being run on measurements.

The specific risks are practical rather than exotic: additive fluid loss with prescribed diuretics, disturbance of the daily-weight signal that tells someone whether they are retaining fluid, and, in the other direction, extra fluid intake in someone told to restrict it. See Heart Failure.

Older adults deserve a specific mention. Dehydration in an older person presents as confusion, falls and acute kidney injury rather than as thirst, and the thirst mechanism itself is blunted with age. A mild diuretic that would be trivial at 40 is not necessarily trivial at 80, particularly in hot weather or during an illness with reduced intake.

Drug Interactions

Begin with the correct translation of the monograph’s interaction section, because it is the sentence most often misread on this whole site.

“No interactions reported” means no interaction study has been performed. It is a statement about the absence of data, not the presence of safety. For a herb taken by people on multiple prescriptions, that absence is not neutral — it is the gap where a problem would sit undetected.

The cautions below therefore rest on mechanism and on the standard handling of diuretic agents, and each is labelled with how much it rests on.

Prescription diuretics — furosemide, bumetanide, hydrochlorothiazide, chlortalidone, indapamide. Mechanistic, and standard practice. Additive fluid and electrolyte loss; the practical failure mode in older adults is dehydration presenting as confusion, a fall or acute kidney injury.
ACE inhibitors and ARBs — ramipril, lisinopril, losartan, valsartan and the rest. Mechanistic. These raise serum potassium as part of how they work. A daily potassium-containing tea is an uncounted addition to that.
Potassium-sparing diuretics and mineralocorticoid antagonists — spironolactone, eplerenone, amiloride, triamterene. Mechanistic, and the highest-risk combination on this list. These are the drugs that cause clinically important hyperkalaemia, and they are prescribed in exactly the heart-failure and kidney-disease populations that also buy kidney herbs.
Potassium supplements and potassium-based salt substitutes. Arithmetic. Salt substitutes are largely potassium chloride and are often adopted, sensibly, by the same people. Two “healthy” choices stacking is a common route to a high reading.
Lithium. Mechanistic and precautionary; not documented for this herb. Lithium is handled by the kidney like sodium, so anything that alters renal sodium and water handling can change lithium levels, and lithium has a narrow therapeutic window. This is the standard caution attached to every diuretic herb, and it should be respected even though nobody has studied it here.
NSAIDs, in combination. Mechanistic extension of a documented drug interaction. The combination of an NSAID with a diuretic and an ACE inhibitor or ARB is a recognised cause of acute kidney injury — sometimes called the “triple whammy” — and has been quantified for those drug classes; see PubMed: diuretics, ACE inhibitors or ARBs with NSAIDs and acute kidney injury. Whether a mild herbal aquaretic meaningfully contributes has not been studied. We flag it as reasoning, not as a reported event.
Glucose-lowering drugs. Precautionary. Preclinical glucose-lowering activity is claimed for this plant with no human quantification, so an unmeasured effect added to a measured drug is a reason for awareness rather than alarm.
Cytochrome P450 substrates with narrow margins. Theoretical, and frequently overstated. Polymethoxylated flavones are the compound class most often raised in this context, and some show enzyme interaction in vitro. It is worth correcting a common shortcut here: the grapefruit-juice interaction is attributed principally to furanocoumarins, not to polymethoxyflavones, so “these are like grapefruit compounds” is a loose analogy rather than an established mechanism. No clinical interaction has been documented for this herb. The reasonable position is to mention it if you take a narrow-margin drug, not to treat it as a known hazard.

What Has Never Been Tested

Writing the gaps as a numbered list makes “we do not know” a stated result rather than something the reader has to infer. For cat’s whiskers, the following have not been done, and several are stated outright in the European assessment:

Genotoxicity testing. Not performed.
Carcinogenicity testing. Not performed.
Reproductive and developmental toxicity testing. Not performed. This is why pregnancy and breastfeeding are “not recommended” — a data gap, not a demonstrated harm.
Fertility data. None.
Paediatric data. None; use under 18 is not recommended for that reason alone.
Long-term safety. No systematic data beyond the monograph’s two-week self-treatment limit, despite the herb being drunk daily for years in its home region.
Human pharmacokinetics. No published absorption, distribution, metabolism or excretion study for the marker compounds at drinkable doses — which is why no dose on any label can be connected to a blood or urine concentration.
Formal interaction studies. None, with any drug class.
Studies in renal impairment. None — in the population most likely to take it, and the one the contraindication names.
Potassium content per dose of finished product. Not declared on labels and, as far as we can find, not published for commercial preparations.

Item 9 is the one to sit with. The herb is contraindicated in severe renal disease, is bought by people with renal disease, and has never been studied in renal disease.

Hazards Cat’s Whiskers Does Not Have

Naming what a herb is not guilty of is as much a part of accuracy as naming what it is, and a reader arriving from other pages on this site may reasonably wonder about each of these.

No arbutin, no hydroquinone, and therefore no uva-ursi-style toxicity ceiling. Uva ursi’s duration limit exists because its proposed active moiety is hydroquinone. Cat’s whiskers has no equivalent compound. Its two-week limit is a different kind of rule entirely — a prompt to get persistent symptoms diagnosed, not a toxicity cap.
No thiaminase. Horsetail carries an enzyme that destroys thiamine, which combined with its diuresis justifies a duration limit. Nothing comparable is reported here.
No aristolochic acid. This is the genuine herbal nephrotoxin — the cause of the Balkan and “Chinese herb” nephropathies, with a documented trail of kidney failure and urothelial cancer. It comes from Aristolochia species, an entirely unrelated family. A reader worried about herbs damaging kidneys is usually, and rightly, thinking of that story; it has nothing to do with this plant. Background: PubMed: aristolochic acid nephropathy.
Not a pyrrolizidine-alkaloid plant. Those alkaloids characterise certain borages, ragworts and their relatives, not the mint family. But — and this is a supplier question rather than a botany one — alkaloid contamination of herbal teas commonly arrives from weeds co-harvested in the same field, so “this species does not make them” does not guarantee “this bag does not contain them.” That risk attaches to loosely sourced bulk leaf generally, and is addressed by batch testing and reputable sourcing, not by botanical identification.
No caffeine. Whatever else it does, it will not keep you awake, and it is not a stimulant diuretic.
No stimulant-laxative anthranoids, and no reported cathartic effect.
No cluster of liver-injury reports.

One more check, run and reported even though it came back clear. A herb’s common name sometimes smuggles in a safety implication the plant does not deserve. Here, every local name — kumis kucing, misai kucing, râu mèo, yaa nuat maeo, “cat’s whiskers” — simply describes the long protruding stamens. No claim is smuggled in. The one name that does carry an implication is the European one: calling a licensed medicinal product “java tea” frames it as a beverage, and beverages do not get the mental brakes that medicines get. That is precisely the framing under which someone drinks four cups a day for three years without ever considering it a dose.

Identity: Why a Certificate Does Not Settle It

A safety discussion assumes you know what is in the packet. For this plant that assumption needs checking, for two independent reasons.

The English name collides. “Cat’s whiskers” is also used for Cleome gynandra, an unrelated African and Asian leaf vegetable, and occasionally for Tacca species. Neither is Orthosiphon and neither is used for urinary complaints. A product labelled only “cat’s whiskers,” with no binomial, is not adequately identified.

The marker compound does not authenticate the species. Products are standardised to sinensetin, and the European Pharmacopoeia sets a minimum sinensetin content. But sinensetin is a polymethoxyflavone that also occurs in citrus — its name records that origin. A certificate of analysis reporting sinensetin therefore establishes that the sample contains sinensetin. It does not establish that the sample is Orthosiphon leaf. Marker assays are potency checks; only DNA-based methods such as ITS2 or rbcL barcoding are identity checks.

Put those together and the practical rule is unglamorous. Look for the binomial (Orthosiphon aristatus or Orthosiphon stamineus), the plant part (leaf, not aerial parts, not root), the extraction solvent and drug-to-extract ratio if it is an extract, and a batch number. European traditional-herbal-registration products carry a registration number and a leaflet, and are the most reliably identified material available. Loose market leaf with no Latin name is the least.

“Supports Kidney Function” Is Not a Measurable Claim

This phrase is on a great many labels and it is worth taking apart, because it is engineered to be unfalsifiable. “Supports” names no direction, no magnitude and no timescale, and “kidney function” names no variable. There is no observation that could contradict it, which is precisely why it is used.

Kidney function is not vague at all. It is one of the most routinely quantified things in medicine, and a product claiming to support it could be judged against any of the following:

Estimated glomerular filtration rate, from serum creatinine — the standard measure of how much filtering the kidneys are doing.
Cystatin C, a second and often more accurate filtration marker, unaffected by muscle mass. See Cystatin C.
Urine albumin-to-creatinine ratio, the earliest and most sensitive marker of kidney damage and the best predictor of progression.
Serum potassium, sodium and bicarbonate, on a basic panel. See Basic Metabolic Panel and Comprehensive Metabolic Panel.
24-hour urine volume and electrolytes, which measure the flushing the product actually claims.
Blood pressure, the single largest modifiable driver of kidney decline.

Not one of these has been reported for cat’s whiskers in an adequately controlled human study. That is a striking gap for a herb whose entire identity is renal, and it is the reason “supports kidney function” survives: measuring it would end it. If you want to know whether anything is helping your kidneys, the tests above answer the question in a way no label can. See Kidney Function Tests.

Practical Rules

Condensed, for a reader who wants the operational version.

Healthy kidneys, no relevant medicines, a couple of cups a day, up to two weeks — this is the traditional use and it is reasonable. Drink enough water alongside; the licensed effect depends on it.
Any chronic kidney disease: ask first, and get potassium and kidney function checked if you proceed.
Heart failure or any fluid restriction: this is the formal contraindication. Not a caution — a contraindication.
On a prescription diuretic, ACE inhibitor, ARB, spironolactone or lithium: mention it to whoever prescribes. The interaction file is empty because nobody looked, which is a reason to tell someone rather than a reason to relax.
On a potassium restriction: count it, or do not drink it. Nobody else will count it for you.
Stop and seek care for fever, painful urination, spasms, blood in the urine, or flank pain. The monograph names these, and the urinary page explains why.
Two weeks, then reassess. Persistent urinary symptoms are a reason for a diagnosis, not for a longer course of tea.
Not in pregnancy or breastfeeding, and not under 18 — on absent data rather than demonstrated harm, which is still the right call for a diuretic.
Buy it with a Latin name on the label, and prefer a registered product where one is available.
Do not substitute it for urate-lowering therapy, antibiotics, antihypertensives or stone prevention that a clinician has prescribed. Those have evidence. This has tradition.

Key Research and Reference Sources

Citations are PubMed topic searches, with titles and journals given in prose where a specific paper is meant, so a link can never resolve to the wrong record. Regulatory documents are named rather than linked to a database entry.

European Union herbal monograph on Orthosiphon aristatus (Blume) Miq. var. aristatus, folium, and its accompanying assessment report, published by the European Medicines Agency’s Committee on Herbal Medicinal Products. The source of the indication, doses, contraindications, the “none known” adverse-effect statement, the 3% potassium figure and the statement that genotoxicity, carcinogenicity and reproductive toxicity testing were not performed. Available through the EMA’s herbal medicines pages, linked under External Resources on the Benefits hub.
Gut microbiota of pigs metabolizes extracts of Filipendula ulmaria and Orthosiphon aristatus — herbal remedies used in urinary tract disorders. Planta Medica, 2022. Why the constituents absorbed differ from the constituents in the leaf. PubMed search
Analysis of the chemical constituents and their metabolites in Orthosiphon stamineus Benth. PLoS One, 2024. The modern constituent inventory behind the chemistry on this page. PubMed search
Topic search — Orthosiphon stamineus toxicity and subchronic safety. The whole toxicology file for this plant, which is smaller than the pharmacology file.
Topic search — hyperkalaemia in chronic kidney disease on renin-angiotensin blockade. Why an uncounted potassium source matters in this specific group.
Topic search — diuretics plus renin-angiotensin blockade plus NSAIDs and acute kidney injury. The documented drug-level version of the “triple whammy.”
Topic search — potassium-based salt substitutes and hyperkalaemia. The commonest uncounted potassium source, and a close analogue of the argument here.
Topic search — aristolochic acid nephropathy. The real herbal kidney disaster, included to make clear this plant has nothing to do with it.
Topic search — pyrrolizidine alkaloid contamination of herbal teas. Why contamination is a sourcing question rather than a species question.
Topic search — DNA barcoding for herbal product authentication. The only method that answers the identity question.
Topic search — grapefruit juice drug interaction and furanocoumarins. The evidence behind the correction made in the interactions section.
Topic search — cystatin C versus creatinine for estimated GFR. One of the measurements “kidney support” never reports.

Connections

All Herbs
Cat’s Whiskers / Java Tea — the main page, with the full monograph wording and dose table.
Diuretic and Kidney Stone Claims — the flushing mechanism, and the stone red flags.
Urinary Tract Complaints — the red-flag list and why delay is not neutral.
Metabolic and Blood Pressure Research — the marker-compound problem in full.
Kidney Disease — the condition this herb is contraindicated in and marketed to.
Acute Kidney Injury — how dehydration and drug combinations damage kidneys quickly.
Heart Failure — the other named contraindication, and why fluid restriction exists.
Potassium — what the mineral does, and why most people need more of it, not less.
Potassium Toxicity — hyperkalaemia, and why it is silent until it is not.
Kidney Function Tests — BUN, creatinine, eGFR and cystatin C.
Cystatin C — the filtration marker independent of muscle mass.
Basic Metabolic Panel — where a potassium result actually comes from.
Uva Ursi: Hydroquinone Risk — a urinary herb that does have a toxicity ceiling.
Horsetail: Thiaminase and Safety — a diuretic herb capped for a nutrient reason.
Dandelion as a Diuretic — another high-potassium diuretic leaf with the same cautions.
Type 2 Diabetes — a condition that overlaps heavily with the readership of this page.

Back to Table of Contents